Overall, a lower to absent PSMA expression was reported in liver metastases from prostate carcinoma, and an overall low or absent level of PSMA in prostate carcinoma lesions was reported to be related to promotor histone 3 lysine methylation, gain of CpG methylation, and loss of histone 3 lysine 27 acetylation. The gene discussed is FOLH1; the disease is prostate carcinoma.